
Oncology NEWS International
- Oncology NEWS International Vol 15 No 8
- Volume 15
- Issue 8
Normal Number of Melanocytes Defined
A Mayo Clinic physician and his colleagues have defined the normal number of melanocytes that are present in Caucasians' sun-exposed skin.
JACKSONVILLE, FloridaA Mayo Clinic physician and his colleagues have defined the normal number of melanocytes that are present in Caucasians' sun-exposed skin. Until now, there has not been a criterion to distinguish sun damage from early (in situ) melanoma. Lead author Ali Hendi, MD, and his team thought that pathologists and Mohs surgeons may err on the side of overdiagnosing melanoma in sun-damaged skin, leading to additional and unnecessary surgery, complications, or deformity. In the study, disease-free tissue samples were obtained from 149 randomly selected Caucasian patients undergoing Mohs surgery for nonmelanoma skin cancers of the face and neck (Arch Dermatol 142:871-876, 2006). They found that in normal sun-exposed skin, the mean number of melanocytes in a 0.5 mm diameter was 15.6 (range, 6 to 29). Adjacent melanocytes, another indicator used by pathologists to diagnose early melanoma, were present in varying degrees in all but 11% of the samples. Finally, melanocytes were found to descend along the hair follicles, a finding previously attributed only to melanoma in sun-damaged skin. Dr. Hendi said the findings are significant because many surgeons remove tissue until they reach undamaged cells with "normal" melanocyte distribution.
Articles in this issue
about 20 years ago
Younger Age at Brain Tumor Diagnosis Portends Poor Emotional Outcomeabout 20 years ago
Higher Responses in Metastatic Colon Ca When Cetuximab Added to Chemoabout 20 years ago
Triple Targeted Therapy Is Tested in Pts With Solid Tumorsabout 20 years ago
FDA Approves Three-Drug Combination Tablet for HIV-1about 20 years ago
Side Effects Persist 16 Years After Prostate Ca Brachytherapyabout 20 years ago
No Significant QOL Differences for Raloxifene and Tamoxifenabout 20 years ago
Amrubicin Appears Promising in Small-Cell Lung Cancerabout 20 years ago
R-MP Active in Older Pts With Newly Diagnosed Myelomaabout 20 years ago
Sunitinib and Sorafenib Active in Phase II Advanced NSCLC Trialsabout 20 years ago
Takeda Signs Agreement With Galaxy Biotech for HuL2G7



















































